NCT05553639 - HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

April 29, 2024

Study Completion Date

April 29, 2024

Conditions

Prostate Cancer Metastatic

Interventions

BIOLOGICAL

HB-302/HB-301 Alternating 2-Vector Therapy

Alternating Therapy of HB-302 and HB-301. The first 5 doses will be administered every 3 weeks. The 6th dose will be administered 6 weeks after the 5th dose. Subsequent doses will be administered every 6 weeks.

Trial Locations (10)

10032

Columbia University Irving Medical Center, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

30322

Emory University Hospital, Atlanta

33136

University of Miami - Sylvester Comprehensive Cancer Center, Miami

33176

Miami Cancer Institute, Miami

37916

Thompson Cancer Survival Center, Knoxville

91010

City of Hope, Duarte

92069

California Cancer Associates for Research & Excellence (cCARE), San Marcos

97213

Providence Cancer Institute, Portland

08901

The Cancer Institute of New Jersey CINJ Rutgers, New Brunswick